Rani Therapeutics Holdings, Inc.
RANI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | -100% | -83.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $3 | $6 | $7 | $7 |
| G&A Expenses | $4 | $5 | $6 | $5 |
| SG&A Expenses | $4 | $5 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $4 |
| Operating Expenses | $7 | $11 | $12 | $16 |
| Operating Income | -$7 | -$11 | -$12 | -$15 |
| % Margin | – | – | -6,984.3% | -1,455.1% |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$1 |
| Pre-Tax Income | -$8 | -$11 | -$13 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$7 | -$7 | -$9 |
| % Margin | – | – | -4,223.3% | -870.3% |
| EPS | -0.12 | -0.18 | -0.22 | -0.27 |
| % Growth | 33.3% | 18.2% | 18.5% | – |
| EPS Diluted | -0.12 | -0.18 | -0.22 | -0.27 |
| Weighted Avg Shares Out | 37 | 37 | 33 | 33 |
| Weighted Avg Shares Out Dil | 37 | 37 | 33 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$10 | -$12 | -$14 |
| % Margin | – | – | -6,711.6% | -1,394.2% |